Category: Lymphoma

Abexinostat is an Orally Available Pan-HDAC Inhibitor

HDAC (Histone deacetylases) are a class of enzymes that remove acetyl groups from an ε-N-acetyl lysine amino acid on a histone. To date, There are 18 human HDACs. Besides, HDACs include four classes on the basis of their homology with yeast proteins. Class I HDACs (HDAC1, 2, 3, and...

ABT-510 is an Anti-Angiogenic Thrombospondin Peptide

Angiogenesis is the growth of new capillaries from existing blood vessels. Steps toward angiogenesis include protease production, endothelial cell migration, and proliferation, vascular tube formation, anastomosis of newly formed tubes, synthesis of a new basement membrane, and incorporation of pericytes and smooth muscle cells. The process of angiogenesis is...

MPM-1, an Anticancer agent, is a Marine Eusynstyelamides Mimic

Autophagy  is the natural and conservative degradation of cells. Specifically, it can remove unnecessary or dysfunctional components through lysosomal-dependent regulation mechanisms. Besides, it allows the orderly degradation and recycling of cellular components. It eliminates molecular and subcellular elements through lysosomal-mediated degradation. This includes nucleic acids, proteins, lipids, and organelles...

Golcadomide is an Orally Active CRBN E3 Ligase Modulator (CELMoD)

Protein degradation agents based on the ubiquitin-proteasome pathway include a part of molecular glues. A molecular glue is a small molecule that stabilizes the interaction between two proteins that do not normally interact. If one of the proteins is ubiquitin ligase, molecular glue can cause another protein to undergo...

Parsatuzumab (RG 7414) is a Humanized mAb, Binding to EGFL7

Epidermal Growth Factor like domain 7 (EGFL7) is an endothelial cell-derived factor, mostly expressed in endothelial cells. EGFL7 takes part in the regulation of the spatial arrangement of cells during vascular tube assembly. The Egfl7 gene encodes active miR-126 which is related to cardiovascular diseases as well as the...

Tirabrutinib is a Selective BTK Inhibitor

The BTK kinases comprise 5 structural domains, including pleckstrin homology, TEC homology, Src homology, Src homology, and kinase domains. The activation of BTK kinase depends on recruitment to the plasma membrane via the pleckstrin homology domain. In humans, BTK mutations result in arrested B-cell development. Besides, it leads to...

Repotrectinib is a potent ROS1 and TRK Inhibitor

Repotrectinib is a potent ROS1 (IC50=0.07 nM) and TRK (IC50=0.83/0.05/0.1 nM for TRKA/B/C) inhibitor. The IC50 values are 0.83/0.05/0.1 nM for TRKA/B/C, respectively. Repotrectinib potently inhibits WT ALK (IC50=1.01 nM). Repotrectinib inhibits mutant ALKs. It inhibits ALK G1202R with an IC50 of 1.26 nM. Besides, it inhibits ALK L1196M with an IC50 of 1.08 nM)....